Zimmer Biomet Holdings, Inc. $ZBH Stock Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 65.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,415 shares of the medical equipment provider’s stock after selling 21,353 shares during the period. Jefferies Financial Group Inc.’s holdings in Zimmer Biomet were worth $1,014,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of ZBH. BlackRock Inc. acquired a new stake in shares of Zimmer Biomet in the second quarter valued at $1,344,282,000. Primecap Management Co. CA acquired a new position in Zimmer Biomet during the 2nd quarter worth $328,578,000. Bank of America Corp DE acquired a new position in Zimmer Biomet during the 2nd quarter worth $187,480,000. Equity Investment Corp acquired a new position in Zimmer Biomet during the 2nd quarter worth $144,748,000. Finally, Legal & General Group Plc purchased a new stake in Zimmer Biomet during the 2nd quarter worth about $126,167,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ZBH shares. Truist Financial set a $114.00 price target on Zimmer Biomet in a research report on Thursday, November 5th. Royal Bank Of Canada boosted their price objective on Zimmer Biomet from $110.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Argus restated a “buy” rating and set a $125.00 target price on shares of Zimmer Biomet in a research note on Thursday, October 22nd. Stifel Nicolaus set a $125.00 target price on shares of Zimmer Biomet in a report on Wednesday, November 4th. Finally, Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $103.00 to $113.00 and gave the company an “equal weight” rating in a report on Thursday, November 5th. Seven research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $112.74.

Zimmer Biomet Stock Down 1.3%

NYSE:ZBH traded down $1.38 during trading hours on Friday, hitting $103.18. The company’s stock had a trading volume of 2,517,489 shares, compared to its average volume of 2,379,990. The stock has a market capitalization of $19.53 billion, a P/E ratio of 26.12, a price-to-earnings-growth ratio of 2.45 and a beta of 0.50. The stock has a fifty day moving average of $95.76 and a 200-day moving average of $92.57. The company has a current ratio of 1.46, a quick ratio of 0.79 and a debt-to-equity ratio of 0.49. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $112.54.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. The company had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2.04 billion. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. Zimmer Biomet’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm earned $1.90 earnings per share. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.56 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 24.30%.

Insider Activity

In related news, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Chad F. Phipps sold 3,000 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by company insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.